Methods applied in addition

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Chapter 6 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.

WT ospti1a EV HAstrepII -OsPti1a OsPti1a -HAstrepII OsPti1a CBB WB: anti-HA antibody BA C OsPti1a -HAstrepII EV ospti1aWT EV HAstrepII -OsPti1a.

Chapter 6 PART II: Concepts in Molecular Biology and Genetics The Human Genome: Implications for the Understanding of Human Disease Companion site for.

Ishida et al. Supplementary Figures 1-3 Page 1 Supplementary Fig. 1. Stepwise determination of genomic aberrations on chr-13 in medulloblastomas from Ptch1.

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas Helen P. Kourea, Irene Orlow, Bernd W. Scheithauer,

Supplemental Data Figure 1: Reverse phase-HPLC of atrial extract from subject 3. Each fraction was assayed with three separate immunoassays: N-terminal.

Detection of Exon 12 Mutations in the JAK2 Gene

Supplemental Data Figure 2: Reverse phase-HPLC of ventricle extract from subject 3. Each fraction was assayed with three separate immunoassays: N-terminal.

A Robust Network of Double-Strand Break Repair Pathways Governs Genome Integrity during C. elegans Development Daphne B. Pontier, Marcel Tijsterman

5' breakpoint in intron 2 (chr19:1,219,187-1,219,238 shown)

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Figure 1 Monogenic forms of diabetes mellitus

Figure S1. AML550 and AML719 arrays

Supplemental Data Figure 7

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications Vera Grossmann, Andreas Roller, Hans-Ulrich Klein, Sandra Weissmann,

Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center Anthony N. Sireci, Vimla S. Aggarwal, Andrew T.

Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors Manny D. Bacolod, Francis Barany

Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

The influence of immunity on transformation into MLL-ENL–driven AML.

Volume 1, Issue 1, Pages (February 2002)

Supplemental Figure 1 A B C

Mutational Testing to Select Novel Targeted Therapies in AML

A Clinical Grade Sequencing-Based Assay for CEBPA Mutation Testing

Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation Miguel Waterhouse, Dietmar Pfeifer, Milena Pantic,

Comparative Genomic Hybridization Analysis of Astrocytomas

A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses Zachary S. Boyd, Rajiv Raja,

Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets Benjamin P. Lewis, Christopher B. Burge,

AGEseq: Analysis of Genome Editing by Sequencing

Volume 17, Issue 1, Pages (January 2010)

Volume 29, Issue 5, Pages (May 2016)

Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

Chapter 24 Genomics and DNA Sequencing

Detection of Exon 12 Mutations in the JAK2 Gene

Rapid Detection of TEM-Type Extended-Spectrum β-Lactamase (ESBL) Mutations Using Lights-On/Lights-Off Probes with Single-Stranded DNA Amplification Kenneth.

Area Models A strategy for Multiplication

Supplemental Figure 1 1 mutation 2 mutations 3 mutations 4 mutations

Genomic cis-Regulatory Architecture and trans-Acting Regulators of a Single Interneuron-Specific Gene Battery in C. elegans Adam S Wenick, Oliver Hobert

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Supplemental Figure 3 A B C T-DNA 1 2 RGLG1 2329bp 3 T-DNA 1 2 RGLG2

Altered Interphase Fluorescence in Situ Hybridization Profiles of Chromosomes 4, 8q24, and 9q34 in Pancreatic Ductal Adenocarcinoma Are Associated with.

Mapping Global Histone Acetylation Patterns to Gene Expression

Detailed Characterization of Alterations of Chromosomes 7, 9, and 10 in Glioblastomas as Assessed by Single-Nucleotide Polymorphism Arrays Inês Crespo,

Volume 125, Issue 7, Pages (June 2006)

Figure S1: An overview of the variants in signalling pathways and molecular processes known to be affected in SMZL, which were identified by whole exome.

Array Comparative Genomic Hybridization Detects Chromosomal Abnormalities in Hematological Cancers That Are Not Detected by Conventional Cytogenetics

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Genomic Technologies and the New Era of Genomic Medicine

Figure Overview.

Figure Overview.

Strategy for Robust Detection of Insertions, Deletions, and Point Mutations in CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing.

Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors Manny D. Bacolod, Francis Barany

Improved Detection of KIT Exon 11 Duplications in Formalin-Fixed, Paraffin-Embedded Gastrointestinal Stromal Tumors Jerzy Lasota, Bartosz Wasag, Sonja.

Chapter 4 Genes, Genomes and DNA

Figure 1. Ability of fluconazole to improve survival of G

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Hirokatsu Yanagihori, Noritaka Oyama, Koichiro Nakamura, Fumio Kaneko

Changes in mutation rate or protein abundance are not observed in HATs when comparing rho+ to rho0 cells. Changes in mutation rate or protein abundance.

The sh339 and qmc554 alleles of gfi1b.

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Presentation by: Bryan Lopez UCF - BSC 4434 Professor Xiaoman Li

Diagonal lines were shown.

Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania Erin L. Crowgey,

The long tail of mutational hotspots in cancer.

Mutational Analysis of Ionizing Radiation Induced Neoplasms

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Presentation transcript:

Methods applied in addition Supplemental Figure 1 A Total cohort: 467 RUNX1 mutated AML Selected cohort: 163 cases n = 321 69% n = 53 11% n = 93 20% RUNX1 WT loss (48: CN-LOH, 5: deletion) n = 53 33% n = 56 34% > 1 RUNX1 mutation 1 RUNX1 mutation n = 54 33% B Methods applied Methods applied in addition cytogenetics sequencing of RUNX1 genomic array in all cases with RUNX1 mutation load >50% mutation analyses of 28 genes genomic arrays survival analysis Supplemental Figure 1: Overview of cases and applied methods. (A) the composition of cases is shown for the total cohort (left panel) and for the selected cohort (right panel) of cases. (B) Applied methods for the total cohort of 467 cases (left column) and for the selected cohort (right column) of cases.

Supplemental Figure 2 n = 3 n = 15 2 mutations 3 mutations 4 mutations n = 75 Supplemental Figure 2: Number of mutations in cases with >1 RUNX1 mutation. (A) the number of cases with 2, 3 and 4 mutations is depicted.

+ + + + + + Supplemental Figure 3 RUNX1 WT loss + ≥2 additional mutations 3 months >1 RUNX1 mutation + ≥2 additional mutations 14 months >1 RUNX1 mutation + 0 or 1 additional mutation 17 months 1 RUNX1 mutation + ≥2 additional mutations 20 months RUNX1 WT loss + 0 or 1 additional mutation 36 months 1 RUNX1 mutation + 0 or 1 additional mutation not reached Overall survival Supplemental Figure 3: Summary of overall survival. Overall survival (depicted by arrows) was determined in the subgroups of RUNX1 WT loss (dark grey), >1 RUNX1 mutation (grey) and 1 RUNX1 mutation (light grey) in combination with ≥2 additional molecular mutations (dark grey) or <2 additional molecular mutations (light grey).